Navigation Links
Spirit of ovarian cancer advocate keeps fundraising drive on track
Date:4/20/2010

PHOENIX, Ariz. April 20, 2010 The Anne Rita Monahan Foundation recently presented $15,000 for ovarian cancer research to the Translational Genomics Research Institute (TGen).

That amount brings to $50,000 the total amount raised by the organization named for Anne Rita Monahan, a Phoenix woman who used her initials to encourage women to "ARM yourself against ovarian cancer."

Funds were raised at the 2nd annual Tea for TEAL, the color associated with ovarian cancer. The English-style tea for 160 people was held Feb. 2 at the Sheraton Phoenix Downtown Hotel, the first time the event was held after Monahan lost her battle to ovarian cancer in May. She was 47.

"I still felt her presence there," said Richard Corley, Treasurer of the ARM Foundation and a life-long friend of Monahan. "It was very sad for her not to grace the event. She had such a personality. Everyone would have wanted to hear what she had to say."

Monahan started her foundation in 2007, six years after she was diagnosed with ovarian cancer, with the mission to eradicate this disease. Her foundation has continued her efforts to make woman aware of the signs and symptoms of ovarian cancer, to encourage early detection, minimize misdiagnosis and fund research into developing evidence-based rationales for precision therapy and a reliable screening test.

A 3rd annual Tea for TEAL is planned next spring, perhaps closer to Mother's Day, said Rachel Busch, President of the ARM Foundation. "I'd like to see us continue with Anne's dream."

That includes eventually reaching Monahan's fundraising goal of $100,000 for TGen's ovarian cancer research.

Dr. Heather Cunliffe, Head of TGen's Breast and Ovarian Cancer Research Unit, said the ARM Foundation has enabled TGen to work with two hospitals with two additional sites approved for launch shortly to consent ovarian cancer patients to donate excess tissues to facilitate TGen's research effort.

"We have Anne's photos all over our lab," Dr. Cunliffe said. "She is really an inspiration, and her personal story empowers us to find a solution as fast as possible. Anne's determination and passion to eradicate ovarian cancer intensifies our efforts."

TGen launched a prospective biospecimen acquisition protocol in June 2009 with the aim of collecting 100 ovarian tumors for research. Biospecimens are preserved following strict procedures designed by Dr. Cunliffe's lab to facilitate state-of-the-art genomic characterization of ovarian cancer. Outcomes anticipated include advanced diagnostic and predictive measures to guide optimal treatment decisions.

"This is a highly heterogeneous and complex disease," Dr. Cunliffe said. "The technology we have available today is ideally suited to solving the severe problem of drug-resistant ovarian cancer. A significant additional benefit will be identification of more robust diagnostic biomarkers for the earlier detection of disease onset".

"Anne would be so proud of that," Corley said. "Thirteen women fighting ovarian cancer today are allowing TGen to make discoveries that will benefit women newly diagnosed with ovarian cancer all because of the work that she started."

Michael Bassoff, President of the TGen Foundation, said funds from the ARM Foundation are making a significant difference in advancing research into ovarian cancer. "We are honored to be carrying on the work inspired by Anne Rita Monahan. Her legacy will be earlier diagnostics and smarter treatments for patients with this devastating disease."

Monahan was an honors graduate of Boston College in Business Administration, earned a Masters of Business Administration at Arizona State University, and retired as a small-business counselor with Maricopa County.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Smells like bees spirit
2. The pill for ovarian cysts
3. Dietary factors influence ovarian cancer survival rates
4. Disarming specialized stem cells might combat deadly ovarian cancer
5. Assessing lead time of selected ovarian cancer biomarkers
6. FDA approved leukemia drugs shows promise in ovarian cancer cells
7. Nanoparticle-delivered suicide genes slowed ovarian tumor growth
8. 2 reproductive factors are important predictors of death from ovarian cancer
9. Genetic factors implicated in survival gap for breast, ovarian or prostate cancer
10. Ovarian transplantation: First baby is born after a new technique
11. Ovarian transplantation: New technique gives greatly improved results in this delicate operation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: